TUDCA (tauroursodeoxycholic acid) is a bile acid that reduces ER stress via two mechanisms: it stabilizes the ER membrane to reduce accumulation of misfolded proteins, and it activates the unfolded protein response in a way that promotes adaptive rather than apoptotic outcomes. It also reduces mitochondrial membrane permeability transition, which is the step that commits a cell to apoptosis under ER stress. It crosses the BBB and acts directly in neurons. Clinical use is primarily in cholestatic liver disease, which is why the safety profile is well-established.
The off-season pairing with AF710B covers the ER stress repair target from two different angles. AF710B works through sigma-1 receptor agonism, which organizes ER-mitochondria contact sites and normalizes calcium homeostasis between organelles — a structural approach. TUDCA works through UPR pathway modulation and direct ER membrane stabilization — a proteostatic approach. Both address the ER stress that accumulates during high-output semesters (sustained receptor synthesis demand, high neurotransmitter turnover), and their mechanisms don’t overlap. Low-risk enough to run year-round as background neuroprotection if desired; cost is low.